ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - atezolizumab - תרכיז להכנת תמיסה לאינפוזיה - atezolizumab 60 mg/ml

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - atezolizumab - תרכיז להכנת תמיסה לאינפוזיה - atezolizumab 60 mg / 1 ml

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - nivolumab - תרכיז להכנת תמיסה לאינפוזיה - nivolumab 10 mg/ml - nivolumab

ישראל - עברית - Ministry of Health

neopharm scientific ltd - paclitaxel - אבקה לתרחיף לאינפוזיה - paclitaxel 100 mg/vial - paclitaxel

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - tocilizumab - תרכיז להכנת תמיסה לאינפוזיה - tocilizumab 20 mg/ml - tocilizumab - tocilizumab - actemra (tocilizumab) is indicated for reducing signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who had an inadequate response to one or more dmards (disease modifying antirhematic drugs) or tnf antagonists or in whom dmards cannot be used. actemra can be used alone or in combination with methotrexate or other dmards.actemra® has been shown to reduce progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. actemra® is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - אבקה להכנת תמיסה לזריקה - mepolizumab 100 mg - mepolizumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - mepolizumab - תמיסה להזרקה - mepolizumab 100 mg / 1 ml - mepolizumab

ישראל - עברית - Ministry of Health

takeda israel ltd - vedolizumab - אבקה להכנת תמיסה מרוכזת לעירוי - vedolizumab 300 mg/vial - vedolizumab

ישראל - עברית - Ministry of Health

takeda israel ltd - vedolizumab - תמיסה להזרקה - vedolizumab 158.8 mg / 1 ml - vedolizumab